Cancer Biology and Loss of Cell Cycle Control (2C) - Bio & Biochem

SECTION 1

Historical Context & Motivation

The recognition that cancer arises from aberrant cell division has roots stretching back centuries, yet the molecular underpinnings of this relationship were not elucidated until the latter half of the twentieth century. Early pathologists such as Rudolf Virchow articulated the principle of omnis cellula e cellula — every cell arises from a pre-existing cell — establishing that tumors must originate from the uncontrolled division of host cells rather than from spontaneous generation. This conceptual foundation set the stage for over a century of investigation into the mechanisms governing normal proliferation and the catastrophic consequences of their failure.

The modern era of cancer biology began with the convergence of virology, genetics, and biochemistry in the 1970s and 1980s, when researchers discovered that specific genes could drive malignant transformation. The identification of oncogenes and tumor suppressors provided a molecular vocabulary for understanding cancer, while parallel discoveries of cyclin-dependent kinases (CDKs) and their cyclin partners illuminated the precise biochemical machinery that cancer co-opts. These converging threads established the framework tested on the MCAT: cancer is fundamentally a disease of dysregulated cell cycle control.

1911 • Peyton Rous and Viral Oncogenesis

Rous demonstrated that a filterable agent (later identified as Rous sarcoma virus) could transmit sarcomas in chickens, providing the first evidence that specific genetic elements — later called v-src — could cause cancer.

1971 • Knudson's Two-Hit Hypothesis

Alfred Knudson analyzed retinoblastoma incidence and proposed that two mutational events ("hits") in the RB gene were necessary for tumor formation, establishing the paradigm for tumor suppressor gene inactivation and the concept of loss of heterozygosity.

1982 • Identification of Human Oncogenes

Weinberg, Barbacid, and colleagues independently isolated the RAS oncogene from human bladder carcinoma cells, demonstrating that point mutations in normal cellular genes (proto-oncogenes) could confer transforming activity.

1987–1996 • CDK-Cyclin Machinery Elucidated

Work by Nurse, Hunt, and Hartwell revealed the conserved cell cycle engine driven by cyclin-CDK complexes, earning them the 2001 Nobel Prize and providing the mechanistic link between growth signals and DNA replication.

2000 • Hallmarks of Cancer

Hanahan and Weinberg published their landmark synthesis identifying six (later expanded to ten) hallmarks of cancer, integrating decades of research into a unifying conceptual framework for malignant transformation.

The central question that drives this topic is deceptively simple: how does a single normal cell acquire the capacity for limitless, autonomous proliferation? The answer, as we shall see, lies in the stepwise accumulation of mutations that disable checkpoints, amplify growth signals, and silence apoptotic programs — transforming the exquisitely regulated cell cycle into an engine of unchecked expansion.

SECTION 2

Core Principles of Cell Cycle Control and Its Loss

Before examining how cancer subverts cell cycle regulation, it is essential to understand the normal control architecture. The eukaryotic cell cycle comprises four sequential phases — G₁ (gap 1), S (DNA synthesis), G₂ (gap 2), and M (mitosis) — governed by a series of molecular checkpoints that integrate signals from growth factors, DNA integrity sensors, and metabolic status. Progression through each transition requires the activation of specific cyclin-CDK complexes, and the entire system operates with both positive and negative feedback loops that ensure fidelity.

Proto-Oncogenes → Oncogenes

Proto-oncogenes encode proteins that promote cell growth and division (e.g., growth factors, receptors, signal transducers, transcription factors). Gain-of-function mutations convert them into oncogenes, producing constitutively active or overexpressed products. Only one allele needs to be mutated (dominant effect).

Tumor Suppressor Genes

Tumor suppressors encode proteins that inhibit proliferation or promote apoptosis (e.g., p53, Rb, APC). Loss-of-function mutations in both alleles are typically required for inactivation (recessive at the cellular level), consistent with Knudson's two-hit hypothesis.

Cell Cycle Checkpoints

Three major checkpoints — the G₁/S (restriction point), the G₂/M checkpoint, and the spindle assembly checkpoint — serve as surveillance stations. Cancer cells characteristically bypass one or more of these checkpoints.

Apoptotic Pathways

Intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways serve as fail-safes that eliminate damaged cells. Cancer cells frequently evade apoptosis through overexpression of anti-apoptotic proteins (Bcl-2) or loss of pro-apoptotic regulators (p53, Bax).

Multi-Step Carcinogenesis

Malignant transformation requires the accumulation of 4–7 driver mutations across multiple pathways (Vogelstein model). This explains the age-dependent incidence of most cancers and the multistep progression from normal tissue → hyperplasia → dysplasia → carcinoma in situ → invasive carcinoma.

✦

KEY TAKEAWAY

Think of the cell cycle as a car with an accelerator (proto-oncogenes) and brakes (tumor suppressors). Cancer does not result from a single mechanical failure; rather, it requires both a stuck accelerator and failed brakes simultaneously. A mutation that constitutively activates Ras (jammed accelerator) combined with loss of p53 (severed brake lines) creates a vehicle that accelerates uncontrollably through every checkpoint — this is why cancer is a multi-hit disease requiring concurrent disruption of growth-promoting and growth-inhibiting pathways.

SECTION 3

Visual Explanation: The Cell Cycle and Cancer Checkpoints

The circular diagram represents the four phases of the cell cycle (G₁, S, G₂, M), with G₀ at the center for quiescent cells. Three major checkpoints are annotated with their molecular regulators and the cancer-associated consequences of their loss. The G₁/S restriction point is the most commonly disrupted checkpoint in human cancers, as loss of Rb or overexpression of Cyclin D renders cells mitogen-independent.

As depicted in the diagram, the cell cycle's fidelity depends on a hierarchical system of checkpoints. At the G₁/S restriction point, mitogenic signals converge on the Cyclin D–CDK4/6 complex, which hyperphosphorylates the retinoblastoma protein (Rb), releasing the E2F transcription factors that drive expression of S-phase genes. Once a cell passes this restriction point, it is committed to division regardless of whether extracellular growth signals persist. Cancer cells exploit this irreversibility: loss of Rb function or overexpression of Cyclin D effectively eliminates the gate, allowing cells to enter S phase constitutively.

The G₂/M checkpoint ensures that cells with DNA damage or incompletely replicated genomes do not enter mitosis. Sensor kinases ATM and ATR activate Chk1/Chk2, which phosphorylate and stabilize p53, the "guardian of the genome." p53 then transcriptionally upregulates p21 (a CDK inhibitor), halting the cell cycle. Loss of p53 — the single most commonly mutated gene in human cancers — abolishes this checkpoint, permitting cells with accumulated genomic damage to proceed through mitosis and propagate mutations to daughter cells.

SECTION 4

Molecular Mechanisms of Oncogenic Transformation

Signal Transduction Pathways in Cancer

Normal cell proliferation is governed by a signaling cascade that begins at the cell surface and terminates in the nucleus. A typical pathway proceeds as follows: a growth factor (e.g., EGF) binds its receptor tyrosine kinase (RTK), triggering receptor dimerization and autophosphorylation. Adaptor proteins (Grb2/SOS) then activate the small GTPase Ras by promoting GDP → GTP exchange. Active Ras initiates the MAPK cascade (Raf → MEK → ERK), culminating in the transcriptional activation of genes encoding cyclins and growth-promoting factors. Simultaneously, the PI3K/Akt/mTOR pathway promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins.

Mechanisms of Oncogene Activation

Proto-oncogenes can be converted to oncogenes through several distinct genetic mechanisms. Point mutations (e.g., Ras G12V) lock GTPases in the active conformation, preventing GAP-mediated hydrolysis of GTP. Gene amplification (e.g., HER2/neu in breast cancer) leads to overproduction of receptor proteins, increasing signal sensitivity. Chromosomal translocation (e.g., the Philadelphia chromosome producing the BCR-ABL fusion in chronic myelogenous leukemia) creates chimeric proteins with constitutive kinase activity. Each of these mechanisms represents a gain-of-function event that is dominant at the cellular level — mutation of a single allele suffices to drive proliferative signaling.

Mechanisms of Tumor Suppressor Inactivation

Tumor suppressor inactivation typically requires loss of both functional alleles, consistent with the two-hit hypothesis. The first hit may be an inherited germline mutation (as in familial retinoblastoma or Li-Fraumeni syndrome) or a somatic mutation; the second hit eliminates the remaining wild-type allele through loss of heterozygosity (LOH), which can occur via deletion, mitotic recombination, or epigenetic silencing (promoter hypermethylation). Additionally, dominant-negative mutations in p53 can inactivate the wild-type tetramer, effectively acting as a one-hit mechanism — a critical nuance for MCAT reasoning.

💡

MCAT INTEGRATION POINT

The MCAT frequently tests the distinction between gain-of-function (oncogene) and loss-of-function (tumor suppressor) mutations. Remember: oncogenes act as dominant drivers (one mutant allele sufficient), while most tumor suppressors require recessive inactivation (both alleles lost). The notable exception is p53, which can exhibit dominant-negative behavior due to its tetrameric structure.

SECTION 5

The Hallmarks of Cancer and Multi-Step Carcinogenesis

The Hallmarks of Cancer framework, proposed by Hanahan and Weinberg in 2000 and updated in 2011, provides an organizing schema for the capabilities that normal cells must acquire during malignant transformation. For the MCAT, understanding these hallmarks in the context of cell cycle regulation and signaling pathways is essential, as passage-based questions frequently require you to map a described experimental finding onto the appropriate hallmark.

This radial diagram depicts the six classical hallmarks of cancer originally described by Hanahan and Weinberg. Each hallmark is connected to the central cancer cell and annotated with representative molecular mediators. For the MCAT, the most high-yield hallmarks relate directly to cell cycle control: self-sufficiency in growth signals (oncogene activation), insensitivity to anti-growth signals (tumor suppressor loss), and evasion of apoptosis.

Hallmark	Normal Regulation	Cancer Disruption	Example Genes
Self-sufficiency in growth signals	Mitogen-dependent cyclin D expression	Constitutive Ras/MAPK signaling; autocrine growth factor loops	RAS, MYC, HER2, EGFR
Insensitivity to anti-growth signals	Rb sequesters E2F; p53 activates p21; TGF-β signaling	Rb loss, CDK4/6 amplification, TGF-β pathway disruption	RB1, TP53, CDKN2A (p16), SMAD4
Evasion of apoptosis	Bax/Bak pore formation; caspase activation cascade	Bcl-2 overexpression; IAP upregulation; p53 loss	BCL2, TP53, BAX, APAF1
Limitless replicative potential	Telomere shortening → senescence (Hayflick limit)	Telomerase reactivation maintains telomere length indefinitely	TERT, TERC
Sustained angiogenesis	Balance of pro- and anti-angiogenic factors	VEGF overexpression; angiogenic switch in hypoxic tumors	VEGF, HIF-1α, TSP-1
Tissue invasion & metastasis	E-cadherin–mediated adhesion; basement membrane integrity	EMT, E-cadherin downregulation, MMP secretion	CDH1, MMP2/9, SNAIL, TWIST

Classical hallmarks of cancer with normal regulators, cancer-associated disruptions, and key gene examples.

The Vogelstein model of colorectal carcinogenesis exemplifies multi-step carcinogenesis and is a frequently tested concept. This model describes a well-characterized progression: loss of the APC tumor suppressor (a negative regulator of the Wnt/β-catenin pathway) initiates hyperproliferation of colonic epithelium. Subsequent activating mutations in KRAS drive progression to adenoma, followed by loss of SMAD4 (disrupting TGF-β signaling) and finally loss of TP53, which permits the transition to invasive carcinoma. This ordered accumulation of mutations illustrates why cancer incidence increases with age — each successive mutation is a stochastic event, and the probability of acquiring all necessary hits increases over a lifetime.

SECTION 6

Worked Example: Analyzing an MCAT-Style Passage

The following worked example simulates the type of reasoning required on the MCAT Biological and Biochemical Foundations section, where you must integrate passage information with your knowledge of cell cycle regulation and cancer biology.

📝

PASSAGE EXCERPT

Researchers studied a familial cancer syndrome in which affected individuals develop bilateral kidney tumors at a mean age of 12 years, compared to a mean age of 58 years for sporadic unilateral cases. Genetic analysis revealed that all affected family members carried a germline heterozygous deletion in the short arm of chromosome 11. Tumor tissue from affected patients showed loss of the remaining wild-type allele in 95% of cases.

Which gene is most likely affected, and what model explains the inheritance pattern?

1
Step 1 — Identify the Pattern

The passage describes bilateral tumors at young age in familial cases versus unilateral tumors at older age in sporadic cases. This pattern — earlier onset and bilateral presentation in hereditary forms — is the hallmark signature of a tumor suppressor gene inherited according to Knudson's two-hit hypothesis.

Pattern matches Knudson's two-hit model for tumor suppressor inactivation.
2
Step 2 — Map the Chromosomal Location

The germline deletion is on the short arm of chromosome 11 (11p). The classical tumor suppressor gene located at 11p13 is the WT1 gene, associated with Wilms tumor (nephroblastoma). This is consistent with the childhood kidney tumors described in the passage.

Gene: WT1 at chromosome 11p13 (Wilms tumor suppressor).
3
Step 3 — Explain the Inheritance and Second Hit

Affected family members inherit one mutant allele (first hit = germline deletion). Every kidney cell already carries one defective copy, so only a single somatic event (second hit) is needed to inactivate the remaining allele. This second hit occurs via loss of heterozygosity (LOH), as confirmed by the 95% LOH rate in tumor tissue. In sporadic cases, both hits must occur somatically in the same cell — a statistically rare double event — explaining the later onset and unilateral presentation.

Familial: 1 germline hit + 1 somatic hit → early, bilateral. Sporadic: 2 somatic hits → late, unilateral.
4
Step 4 — Distinguish from Oncogene Activation

If this were an oncogene, the inheritance pattern would be dominant with full penetrance from a single activating mutation — you would not expect LOH, and the gene product would be constitutively active rather than absent. The recessive loss-of-function pattern at the cellular level (despite autosomal dominant inheritance at the pedigree level) is diagnostic of a tumor suppressor gene.

Final Answer: WT1 tumor suppressor; Knudson's two-hit hypothesis with LOH as the second event.

SECTION 7

Oncogenes vs. Tumor Suppressors: A Comparative Framework

A robust command of the distinctions between oncogenes and tumor suppressor genes is indispensable for MCAT success. These two gene classes represent complementary sides of the same regulatory coin, and exam questions frequently require you to classify a described mutation as one or the other based on its functional consequences, inheritance pattern, or experimental behavior.

Feature	Oncogenes	Tumor Suppressors
Normal function	Promote cell growth, division, and survival	Inhibit proliferation, promote apoptosis, repair DNA
Mutation type	Gain-of-function (constitutive activation or overexpression)	Loss-of-function (deletion, truncation, silencing)
Alleles required	One (dominant effect)	Both (recessive at cellular level); exception: p53 dominant-negative
Analogy	Stuck accelerator	Broken brake pedal
Activation mechanism	Point mutation, amplification, translocation	Deletion, LOH, promoter methylation, frameshift
Key examples	RAS, MYC, HER2, BCR-ABL, cyclin D1	TP53, RB1, APC, BRCA1/2, p16/CDKN2A
Therapeutic strategy	Inhibit the overactive protein (e.g., imatinib for BCR-ABL)	Restore function or exploit synthetic lethality (e.g., PARP inhibitors for BRCA loss)

Comparative features of oncogenes and tumor suppressor genes relevant to MCAT preparation.

✦

KEY TAKEAWAY

The oncogene/tumor suppressor dichotomy maps onto a fundamental engineering principle: any robust system requires both positive regulators (accelerators) and negative regulators (brakes), and catastrophic failure demands compromise of both control layers. In cancer, this translates to a requirement for concurrent activation of growth-promoting pathways AND inactivation of growth-suppressing pathways. This is why single mutations rarely cause cancer in the absence of additional cooperating events — a concept known as oncogene cooperation.

SECTION 8

Connections to Advanced Cancer Biology

While the MCAT emphasizes the foundational concepts of oncogenes, tumor suppressors, and cell cycle checkpoints, an awareness of more advanced topics can help you navigate challenging passage-based questions that introduce novel experimental findings. Several areas at the frontier of cancer biology extend directly from the principles covered in this lesson.

Foundational Concept (MCAT Core)	Advanced Extension	Clinical Relevance
Oncogene activation (gain-of-function)	Oncogene addiction — tumors become dependent on a single dominant oncogene	Targeted therapy (imatinib for BCR-ABL; vemurafenib for BRAF V600E)
Tumor suppressor loss (LOH)	Synthetic lethality — exploiting parallel repair pathways when one is lost	PARP inhibitors in BRCA1/2-mutant ovarian and breast cancers
Epigenetic silencing of tumor suppressors	Epigenetic therapy — reversing aberrant DNA methylation and histone modifications	DNMT inhibitors (azacitidine) and HDAC inhibitors in hematologic malignancies
Evasion of apoptosis	Immune evasion — cancer cells upregulate PD-L1 to suppress T-cell–mediated killing	Immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies)
Multi-step carcinogenesis	Tumor heterogeneity and clonal evolution — subclonal populations undergo Darwinian selection	Resistance to therapy; liquid biopsy monitoring of tumor evolution

Bridging foundational MCAT concepts to advanced cancer biology and clinical therapeutics.

The concept of tumor heterogeneity deserves particular attention because it explains a pervasive clinical challenge: therapeutic resistance. As a tumor grows, its constituent cells acquire additional mutations at varying rates, creating a genetically diverse population. When a targeted therapy eliminates the dominant clone, resistant subclones — which may have been present at low frequency before treatment — expand to repopulate the tumor. This Darwinian framework for understanding cancer progression represents the natural extension of the multi-step carcinogenesis model you have already mastered. For the MCAT, recognizing that cancer is not a monolithic disease but rather an evolving ecosystem of competing clones will help you reason through experimental passages that describe drug resistance or heterogeneous tumor responses.

ℹ

CONNECTING TO OTHER MCAT TOPICS

Cancer biology interfaces with multiple MCAT content areas: genetics (inheritance patterns, LOH, mismatch repair), biochemistry (kinase cascades, GTPase function, enzyme regulation), molecular biology (DNA repair, transcriptional regulation, epigenetics), and immunology (tumor immune evasion, checkpoint inhibition). Questions may draw from any of these disciplines, so cultivate an integrative understanding rather than siloed memorization.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A researcher identifies a novel gene whose protein product, when overexpressed in NIH-3T3 cells, causes focus formation (foci of transformed cells growing over the monolayer). The transforming activity requires only a single copy of the mutant gene. Is this gene most likely a proto-oncogene or a tumor suppressor gene? Justify your answer by referring to the genetic behavior of each class.

Show answer

This gene is most likely a proto-oncogene that has been converted to an oncogene. The key evidence is that a single copy of the mutant gene suffices for transformation (dominant gain-of-function). Tumor suppressor inactivation is typically recessive at the cellular level, requiring loss of both alleles; a single mutant copy would not be expected to cause transformation in cells that still retain a wild-type allele. The focus formation assay is, in fact, the classical experimental method by which oncogenes such as RAS were originally identified — NIH-3T3 cells that receive an oncogene lose contact inhibition and proliferate into visible foci.

Question 2: BASIC CALCULATION

In a familial cancer syndrome, the first allele of a tumor suppressor is inactivated by a germline mutation. If the somatic mutation rate for the second allele is approximately 10⁻⁶ per cell division, and an organ contains 10⁸ target cells, estimate whether it is likely that at least one cell will acquire the second hit during a patient's lifetime. Assume each target cell divides approximately 10³ times over a lifetime.

Show answer

The total number of cell divisions in the target organ over a lifetime is 10⁸ cells × 10³ divisions = 10¹¹ total divisions. With a per-division mutation rate of 10⁻⁶, the expected number of second-hit events is 10¹¹ × 10⁻⁶ = 10⁵ (100,000) events. This vastly exceeds 1, meaning it is virtually certain that multiple cells will acquire the second hit. This calculation illustrates why familial cancer syndromes — where the first hit is inherited — exhibit near-complete penetrance and early onset. In contrast, sporadic cases require both hits to occur somatically in the same cell lineage, a much rarer event requiring approximately (10⁻⁶)² = 10⁻¹² probability per cell division.

Question 3: INTERMEDIATE

A mutation in the TP53 gene produces a stable protein that can still oligomerize with wild-type p53 monomers but cannot bind DNA. The patient is heterozygous for this mutation. Will this patient's cells retain normal p53 checkpoint function? Explain using your knowledge of p53 structure and the concept of dominant-negative mutations.

Show answer

The patient's cells will not retain normal p53 function. p53 functions as a homotetramer. In a heterozygous cell, both mutant and wild-type monomers are produced in roughly equal amounts. When tetramers assemble randomly, only 1/16 of tetramers will consist entirely of wild-type monomers (probability = (1/2)⁴). Any tetramer containing even one mutant monomer will be functionally impaired because the mutant subunit cannot bind DNA. This means approximately 15/16 (≈94%) of p53 tetramers are non-functional, despite the presence of one wild-type allele. This is a dominant-negative effect, which is a critical exception to the general rule that tumor suppressors require biallelic inactivation. This is why certain TP53 missense mutations ("hotspot mutations") are far more oncogenic than simple deletions.

Question 4: APPLIED

A pharmaceutical company develops a CDK4/6 inhibitor for the treatment of estrogen receptor-positive (ER+) breast cancer. Based on your understanding of cell cycle regulation, explain the rationale for this drug's mechanism of action. Why would this drug be ineffective in tumors that have already lost Rb function?

Show answer

CDK4/6 inhibitors (e.g., palbociclib, ribociclib) work by preventing the phosphorylation of Rb. In ER+ breast cancer, estrogen signaling drives Cyclin D1 expression, which activates CDK4/6. The Cyclin D1–CDK4/6 complex phosphorylates Rb, releasing E2F transcription factors and permitting G₁→S transition. By inhibiting CDK4/6, the drug keeps Rb in its hypophosphorylated, active tumor-suppressive state, thereby arresting cells in G₁. However, if a tumor has already lost Rb function (e.g., through homozygous deletion or mutation), there is no substrate for CDK4/6 to phosphorylate — E2F is constitutively free and active regardless of CDK4/6 status. The drug's target (Rb regulation) is irrelevant when Rb is absent. This illustrates the critical principle that targeted therapies require an intact target pathway, and that Rb status functions as a predictive biomarker for CDK4/6 inhibitor sensitivity.

Question 5: CRITICAL THINKING

A research group discovers that a particular oncogene, when introduced into primary human fibroblasts, does not cause transformation but instead triggers premature cellular senescence. However, when the same oncogene is introduced into fibroblasts with a pre-existing TP53 deletion, robust transformation occurs. Propose a model that explains both observations and discuss the implications for the multi-step nature of carcinogenesis.

Show answer

This experiment demonstrates the phenomenon of oncogene-induced senescence (OIS), a critical tumor-suppressive mechanism. When an oncogene (e.g., activated RAS) is introduced into normal primary cells, the resulting supraphysiological mitogenic signaling triggers a DNA damage response and activates p53, which in turn induces the CDK inhibitor p21 and other senescence effectors. The cell permanently exits the cell cycle as a protective measure — this is why oncogene activation alone is insufficient for transformation in cells with intact tumor suppressor pathways. When TP53 is already deleted, the senescence checkpoint is abolished: the oncogene's proliferative signals proceed unopposed, driving transformation. This model has profound implications for multi-step carcinogenesis: OIS acts as an intrinsic barrier that requires subsequent tumor suppressor loss to be overcome. It explains why oncogene activation and tumor suppressor loss are cooperative events — one creates proliferative pressure, the other disables the fail-safe that would normally neutralize it. Clinically, this is observed in premalignant lesions (e.g., benign nevi containing BRAF V600E mutations) that remain senescent for decades until additional mutations (e.g., p53 or CDKN2A loss) tip the balance toward melanoma progression.

SUMMARY

Lesson Summary: Cancer Biology and Loss of Cell Cycle Control

Summary

Cancer arises from the stepwise accumulation of mutations that disrupt normal cell cycle checkpoints and signaling pathways. Oncogenes are activated through gain-of-function mutations (point mutations, gene amplification, chromosomal translocation) and act dominantly — one mutant allele suffices. Tumor suppressor genes require loss of both alleles (Knudson's two-hit hypothesis), with the notable exception of dominant-negative p53 mutations. The three critical checkpoints — the G₁/S restriction point (governed by Rb and Cyclin D–CDK4/6), the G₂/M checkpoint (governed by p53/p21 and Cyclin B–CDK1), and the spindle assembly checkpoint — collectively ensure genomic fidelity, and their loss is central to malignant transformation.

The Hallmarks of Cancer framework organizes the acquired capabilities of malignant cells: self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. The Vogelstein model of colorectal carcinogenesis (APC → KRAS → SMAD4 → TP53) exemplifies multi-step carcinogenesis and explains the age-dependent incidence of cancer. For the MCAT, mastering the distinction between oncogene activation (dominant, gain-of-function) and tumor suppressor inactivation (recessive, loss-of-function), along with the molecular logic of each checkpoint, provides the foundation for reasoning through any cancer biology passage.